Introduction: Sodium glucose co-transporter 2 inhibitors decrease hemoglobin A1c (HbA1c) and blood pressure (BP) and slightly increase low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus (T2DM). The effects of baseline BP and LDL-C on the safety and efficacy of canagliflozin in patients were analyzed post hoc in a phase III study. Methods: Japanese patients with T2DM were classified by baseline systolic BP (SBP) of\130 or C130 mmHg, diastolic BP (DBP) of \80 or C80 mmHg, and LDL-C of \120 or C120 mg/ dL. Canagliflozin was administered daily to patients for 52 weeks at doses of either 100 mg (n = 584) or 200 mg (n = 715). The effects of canagliflozin on the incidence of adverse events (AEs), BP, and LDL-C were evaluated.
INTRODUCTION
Patients with type 2 diabetes mellitus (T2DM) often have comorbid hypertension and hypercholesterolemia. Comorbidities of these diseases synergistically increase the incidence rates of cerebrovascular and coronary heart diseases [1] [2] [3] [4] . Integrated control of body weight, blood pressure (BP), and serum lipids in addition to blood glucose is essential for the treatment of diabetic patients to decrease the risk of cardiovascular (CV) events [5] [6] [7] , because the goal of diabetes treatment is to improve quality of life and life span of diabetic patients to the same level as those of non-diabetics [8] .
Sodium glucose co-transporter 2 (SGLT2) inhibitors are anti-diabetic agents that correct hyperglycemia by promoting urinary glucose excretion through the inhibition of glucose reabsorption in proximal tubules irrespective of the patient's insulin secretory capacity or insulin resistance. Because this underlying pharmacological mechanism is novel and clearly different from that of existing drugs, SGLT2 inhibitors may present a new treatment option for T2DM.
In various clinical trials in patients with T2DM, administration of SGLT2 inhibitors, including canagliflozin, resulted in a sustained decrease in hemoglobin A1c (HbA1c), body weights, and BP for long periods [9] [10] [11] [12] [13] [14] .
Recently, in the EMPA-REG OUTCOME trial (ClinicalTrials.gov identifier, NCT01131676), empagliflozin significantly reduced the rate of primary composite CV outcome and of death from any cause in patients with T2DM at high CV risk [15] . It was the first evidence to assess the effects of SGLT2 inhibitor on CV outcome. The mechanisms behind the CV benefits of empagliflozin are multidimensional and involve established changes, such as decreasing HbA1c, losing body weight and lowering BP. On the other hand, BP-lowering effects of SGLT2 inhibitors may be mediated at least partly by its diuretic effect, and there is a concern of the risk of dehydration and hypotension. It has been reported that SGLT2
inhibitors increase low-density lipoprotein cholesterol (LDL-C) as a class effect [16, 17] .
Although small increase in high-density lipoprotein cholesterol (HDL-C) was also observed in patients with T2DM, increase in LDL-C raises concerns of a CV risk [10] . Therefore, we investigated the influence of different baseline BPs and LDL-C (as CV risk factors) on the safety and efficacy of canagliflozin by post hoc analysis of data in a 52-week phase III study [13] in Japanese patients with T2DM.
METHODS

Study Design and Patient Population
The present post hoc subgroup analyses were conducted using the data obtained in a phase III study of canagliflozin in Japanese patients with T2DM (multicenter, open-label, and long-term administration) [13] . In this clinical study, canagliflozin was administered once daily for 52 weeks at 100 or 200 mg as monotherapy or as add-on therapy to other oral antihyperglycemic drugs (sulfonylurea, glinide, a-glucosidase inhibitor, biguanide, thiazolidinedione, or dipeptidylpeptidase-4 inhibitor). The study was conducted in patients with T2DM whose blood glucose was inadequately controlled with diet/exercise therapy alone or in combination with an oral antihyperglycemic drug for more than 12 weeks before screening. The complete inclusion and exclusion criteria are described in the original report [13] . The main inclusion criteria were (1) patients C20 years of age, (2) diagnosis of T2DM at least 3 months before the screening, and (3) HbA1c of C7.0% and B10.0%
in monotherapy and of C7.0% and B10.6% in combination therapy. The main exclusion criteria were (1) In the present analyses, patients were classified into subgroups according to their baseline BP or LDL-C: patients with baseline SBP\130 mmHg (S\130) and SBP C130 mmHg (S C 130), patients with DBP \80 mmHg (D\80) and DBP C80 mmHg (D C 80), and patients with LDL-C \120 mg/dL (L\120) and LDL-C C120 mg/dL (L C 120). SBP \130 mmHg, DBP \80 mmHg, and LDL-C \120 mg/dL are the control target levels for SBP, DBP, and LDL-C in Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013 [8] .
Assessments
Safety
Adverse events (AEs) were recorded throughout the study, as described in the original report [13] , and the results for each subgroup are presented in this report. AEs were classified according to the System Organ Class and preferred term of MedDRA/J version 15.1 (Japanese Maintenance Organization, Tokyo, Japan 
Efficacy
Changes in HbA1c, fasting plasma glucose (FPG), and body weight from baseline to week 52 were assessed in each subgroup. The changes in SBP or DBP over the treatment period with the study drug and the change from baseline at week 52 were evaluated in each subgroup according to SBP or DBP categories. In addition, the proportion of patients whose SBP decreased to \130 mmHg and those in whom DBP decreased to \80 mmHg were determined in original S C 130 and D C 80 groups, respectively.
The changes in lipid parameters such as LDL-C, triglyceride, HDL-C, and LDL-C/HDL-C from baseline to week 52 and the changes in LDL-C over the treatment period with the study drug were assessed in each LDL-C subgroup. LDL-C was quantified using the direct method.
Statistical Analysis
All the analyses were conducted for both doses of canagliflozin. Safety analyses were performed in the safety analysis set (N = 1299), which comprised all patients excluding those who did not receive a dose of canagliflozin or who lacked safety data after starting the study drug. AEs were summarized as the number and percentage of patients with AEs. Laboratory variables were shown as the mean ± standard deviation (SD) for the change from the baseline to week 52.
Only patients with data at both baseline and
week 52 or the relevant visit were included in the analyses of safety variables. Statistical analyses were not performed on the safety and laboratory variables between the subgroups.
Efficacy analyses were performed in the full analysis set (N = 1297), which comprised all allocated patients, excluding those without T2DM, those not receiving a dose of the study drug, or those for whom efficacy data after starting the study drug administration was absent. The last observation carried forward method was used to impute missing data at week 52. The changes in HbA1c, FPG, body weight, SBP, DBP, LDL-C, triglyceride, HDL-C, and LDL-C/HDL-C from baseline to week 52 were analyzed using the one-sample t test. All statistical tests were performed two-sided at a 5% significance level. For all statistical analysis, SAS ver. 9.2 (SAS Institute Inc., Cary, NC, USA) was used.
RESULTS
Analysis in Subgroups Classified by Baseline BP
Patient characteristics of subgroups classified by baseline BP are shown in Table 1 . In patients treated with 100 or 200 mg canagliflozin, the number of patients in the S\130 subgroup was almost the same as that in the S C 130 subgroup and the number of patients in the D\80 subgroup was slightly larger than that of the D C 80 subgroup. patients with postural dizziness were in the S\130 and D\80 subgroups. Four had mild or moderate dehydration: two patients were with S\130 and D\80 and two patients were with S C 130 or D C 80 subgroups (data not shown).
The incidence of other AEs including hypoglycemia (including both symptomatic and asymptomatic hypoglycemia), genital infections, osmotic diuresis, and skin and subcutaneous tissue disorders was similar across subgroups. The incidence rate of CV-related AEs was also similar between subgroups at both doses, and moderate lacunar infarction and mild increase of creatine phosphokinase occurred in one event each at 100 and 200 mg, respectively, and were classified as drug-related CV events.
Changes in laboratory variables from baseline to week 52 were similar across subgroups (see Table S2 in the ESM). Hematocrit and BUN increased across subgroups. No changes from baseline in electrolytes (Na, K, Cl, Ca, Mg, and inorganic phosphate) and heart rate were observed in any subgroups at both canagliflozin doses.
HbA1c, FPG and body weight were significantly decreased from baseline to week 52 of treatment with canagliflozin in all subgroups (Table 3 ). The decreases in mean SBP and DBP from the baseline at 52 weeks were larger in S C 130 and D C 80 subgroups than those in S\130 and D\80 subgroups, respectively (Table 3 ). The decreases in mean SBP and DBP in S C 130 and D C 80 subgroups were sustained from 4 to 52 weeks after No clear differences were observed in the incidence rates of other AEs and drug-related AEs between the subgroups classified by baseline LDL-C ( Table 2 and Table S1 ).
Changes of laboratory variables from baseline
to week 52 were similar between subgroups at both doses of canagliflozin (see Table S3 in the ESM).
HbA1c, FPG, and body weight significantly decreased from baseline to week 52 of treatment with canagliflozin in both subgroups (Table 5 ). In L \120 subgroup, LDL-C slightly increased but did not exceed 120 mg/dL after a 52-week administration of either dose (Table 5 ; Fig. 2 ). This LDL-C increase was maintained until week 52. On the other hand, LDL-C in L C 120 subgroup slightly decreased from baseline after administrations of canagliflozin at both doses (Table 5 ). Triglyceride decreased from baseline to week 52, except for L\120 subgroup at the 100 mg dose. HDL-C increased after the 52-week administration to a similar extent in [16] .
The change in LDL-C was observed at 4 weeks of initiation of treatment although the mean LDL-C did not reach 120 mg/dL throughout the treatment period. HDL-C in the overall, L\120, and L C 120 subgroups similarly increased. The triglyceride were decreased in the overall and L C 120 subgroup at the 100 mg dose and the overall, L C 120, and L\120 subgroups at the 200 mg dose. The effects of canagliflozin on lipid metabolism may be mediated through urinary caloric loss by SGLT2 inhibition. Although further investigation is necessary to clarify the mechanism on lipid metabolism, it should be stressed that canagliflozin did not increase the risk of LDL-C elevation in L C 120 subgroup. Indeed, empagliflozin was associated with small increases in LDL-C in the EMPA-REG OUTCOME trial; however, CV risk was reduced in the empagliflozin treated group, as compared with placebo group [15] . The limitations of the study are described as 
